De novo hepatitis B virus (DNHB) infections may occur in recipients who do not receive prophylaxis after liver transplantation (LT) with antibody to hepatitis B core antigen (anti-HBc)-positive donor grafts. Active immunization has been shown to prevent DNHB in pediatric recipients. Our aim is to investigate the efficacy of HBV vaccination for preventing DNHB in adult living donor liver transplantation (LDLT). In total, 71 adult antibody to hepatitis B surface antigen (anti-HBs)-negative LDLT patients who received anti-HBc1 grafts from 2000 to 2010 were enrolled into this study. Patients were given hepatitis B virus vaccinations with the aim of achieving anti-HBs > 1000 IU/L before transplant and >100 IU/L after transplant. The cohort was stratified into 3 groups: patients with pretransplant anti-HBs titer of > 1000 IU/L without the need for posttransplant prophylaxis (group 1, n 5 24), patients with pretransplant low titer of <1000 IU/L who were given posttransplant lamivudine prophylaxis and responded appropriately to posttransplant vaccination by maintaining anti-HBs titers of > 100 IU/L (group 2, n 5 30), and low titer nonresponders (antiHBs titer of < 100 IU/L despite vaccination), for whom lamivudine was continued indefinitely (group 3, n 5 17). All DNHB occurred in group 3 patients with posttransplant anti-HBs levels of < 100 IU/L, with an incidence rate of 17.6% compared with 0% in patients with posttransplant anti-HBs levels of > 100 IU/L (P 5 0.001). A pretransplant anti-HBs level of >1000 IU/L was significantly associated with early attainment and a sustained level of posttransplant anti-HBs of >100 IU/L (P < 0.001). Active immunization is effective in preventing DNHB in adult LDLT if the posttransplant anti-HBs level is maintained above 100 IU/L with vaccination. Antiviral prophylaxis can be safely discontinued in patients who obtain this immunity.
antibody to hepatitis B core antigen (anti-HBc)-positive donors.
(1) The risk for DNHB ranges from 7% to as high as 100%, (2) (3) (4) (5) (6) depending on the serological status of the liver graft recipients; hepatitis B virus (HBV) naive recipients (antibody to hepatitis B surface antigen [anti-HBs]-negative/anti-HBc-) are at the highest risk. (7, 8) Despite the associated risk of DNHB, grafts from anti-HBc1 donors are still used to address the organ shortage in regions where HBV is endemic. (9) It is therefore impractical to exclude donors with antiHBc1 from organ donation. Recent studies have demonstrated that the incidence of DNHB can be Abbreviations: aa, amino acid; anti-HBc, antibody to hepatitis B core antigen; anti-HBs, antibody to hepatitis B surface antigen; CI, confidence interval; DNHB, de novo hepatitis B virus; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LDLT, living donor liver transplantation; LT, liver transplantation; PBC, primary biliary cirrhosis; YMDD mutation, reduced to approximately 0%-11% with the use of posttransplant prophylaxis either with hepatitis B immunoglobulin (HBIG) and/or nucleoside/nucleotide analogues. (8) Because occult HBV infection may persist in antiHBc1 donor grafts despite the use of prophylaxis, most recommendations suggest continuing posttransplant prophylactic treatments indefinitely in recipients who receive anti-HBc1 grafts. (10) However, the prolonged use of nucleoside/nucleotide analogues and HBIG prophylaxis is costly and inconvenient. Active immunization with HBV vaccination could be an economical alternative to traditional forms of posttransplant prophylaxis for DNHB. It is safe, and the effect is more long lasting in comparison to passive immunization (HBIG). Our group and others have demonstrated that maintaining high anti-HBs levels after transplant is effective in preventing DNHB in pediatric recipients of antiHBc1 liver grafts. (11) (12) (13) In fact, the optimal level of anti-HBs titer to prevent DNHB in the adult population is still uncertain. There is a trend that the higher the level of anti-HBs titer, the lower the risk of DNHB. (14) Our study aimed to evaluate the efficacy of active immunization in preventing DNHB in adult living donor liver transplantation (LDLT) and also to assess the effective pretransplant and posttransplant antiHBs levels for preventing DNHB.
Patients and Methods

PATIENT SELECTION
From January 2000 to December 2010, there were 153 adult patients with age 18 years and no HBV infection (negative baseline hepatitis B surface antigen [HBsAg] ) who underwent LDLT at the Kaohsiung Chang Gung Memorial Hospital Medical Center. Of the 153 patients, 71 patients who received liver grafts from anti-HBc1 donors were enrolled in this study with approval of the hospital institutional review board (number 201601962B0).
All donors and recipients were tested for hepatitis serology (HBsAg, anti-HBs, anti-HBc, HBV DNA), using radioimmunoassay (Abbott Laboratories Diagnostics Division, Abbott Park, IL) and Digene Hybrid capture assay (Digene Corp, Gaithersburg, MD). The upper limit of anti-HBs is 1600 IU/L. All donors in this study were negative for HBsAg and HBV DNA except for the presence of anti-HBc, whereas in the recipients, all were negative for HBsAg and HBV DNA.
OPERATIVE MANAGEMENT
Surgical techniques and perioperative care for LDLTs were as described previously. (15, 16) All patients received a standard immunosuppressive therapy with tacrolimus, mycophenolate mofetil, and prednisolone; sirolimus was used in selected patients with impaired renal function or antitumor effects for hepatocellular carcinoma (HCC). Prednisolone was gradually withdrawn 6 months afterward if there was no acute rejection episode.
PREVENTION OF POSTTRANSPLANT DNHB
Prior to liver transplantation (LT), HBV vaccinations with double doses of recombinant HBV vaccine (20 lg, Engerix-B; Smithkline Beecham Biologicals, Rixensart, Belgium) were given to the recipients, with the aim of keeping their anti-HBs titers > 1000 IU/L at the time of transplantation if the recipient condition was stable.
For patients who managed to achieve anti-HBs levels of >1000 IU/L before LT, no antiviral prophylaxis was given after the operation. However, HBV booster vaccinations were administered after tapering of prednisolone (group 1, n 5 24), with regular measurements of anti-HBs titers during follow-up. Vaccinations were administered as needed, with the aim of maintaining titers above 100 IU/L after LT.
For patients who had low anti-HBs titer (<1000 IU/L) at the time of LT, lamivudine (GlaxoSmithKline Inc., Mississauga, Canada) was given at the dose of 100 mg/day for at least 2 years after transplantation, together with the administration of HBV vaccinations after tapering the corticosteroid as described above. In the vaccine responders who had anti-HBs titers steadily above 100 IU/L after vaccinations, lamivudine was discontinued after a minimum period of 2 years (group 2, n 5 30), whereas nonresponders (anti-HBs titer < 100 IU/L even after vaccinations, n 5 17) were placed on lifelong lamivudine therapy (group 3; Fig. 1 ).
POSTTRANSPLANT FOLLOW-UP
HBV serological tests (anti-HBs, HBsAg) and HBV DNA were monitored every 3 months in recipients who received lamivudine and every 6 months in recipients without prophylaxis. Once the titer of anti-HBs declined to < 100 IU/L, booster vaccination was given on the follow-up visit. Tests were performed more frequently during periods of abnormal liver function tests.
DEFINITION OF DNHB
DNHB was defined as HBsAg seropositivity occurring in 2 consecutive tests in the recipient after LT. If a patient became positive for HBsAg, HBV DNA was extracted from the HBsAg 1 sera and was amplified by polymerase chain reaction followed by direct sequencing of the nucleotide sequences encoding the determinant of HBsAg (amino acid [aa] 116-160) using a dye terminator cycle sequencing quick start kit (Beckman Coulter, Fullerton, CA). DNHB was treated with lamivudine (shifting to entecavir when available in 2008), and adefovir dipivoxil (GlaxoSmithKline Inc.) was added if a mutant strain was identified. 
STATISTICAL ANALYSIS
Analysis was performed using SPSS, version 22 (SPSS, Chicago, IL). Categorical data were analyzed using the chi-square test; continuous data were analyzed using the Student t test. The survival rates were calculated using the Kaplan-Meier method with logrank test for significance. A P value of < 0.05 was considered statistically significant.
Results
There were 24, 30, and 17 patients in groups 1, 2, and 3, respectively. No significant differences were noted in the baseline characteristics among the 3 groups (P > 0.05) except that the pretransplant anti-HBs level was significantly higher in group 1 as expected due to the higher pretransplant anti-HBs titer (>1000 IU/L) in this group (P < 0.001; Table 1 ). The median follow-up period was 94 months (range, 23-196 months). In group 2, the median duration on lamivudine was 36 months (range, 23-107 months), and the median follow-up after stopping lamivudine until the end of the study was 100 months (range, 76-196 months).
VACCINATION RESPONSE AND POSTTRANSPLANT ANTI-HBS LEVEL
Of the 71 recipients who received anti-HBc1 liver grafts, 63 patients were vaccinated before transplantation with a median number of 4 doses (range, 1-9); 24 patients (38%) responded and attained anti-HBs titers of >1000 IU/L at the time of transplantation.
Out of the 47 recipients who had low anti-HBs titers (<1000 IU/L) and were given lamivudine after transplantation, 22 patients received posttransplant booster vaccinations. The median time to initiate vaccination was 15 months (range, 6-54 months) after transplant. Of the vaccinated patients, 14 (63.6%) responded and achieved anti-HBs levels of >100 IU/L after a median time of 3.5 months (range, 0-69 months) from the time of vaccination and 29 months (range, 11-76 months) since LT. The mean number of vaccines needed to attain this level was 8 (range, 1-41).
In total, 25 recipients were not given vaccination after transplantation; 16 of them had spontaneous posttransplant anti-HBs titers of >100 IU/L even without vaccination, and another 9 recipients were not given vaccination due to their underlying medical conditions.
The high pretransplant anti-HBs titer group (>1000 IU/L) showed significantly higher absolute anti-HBs titers at 6, 12, and 24 months after transplantation, and a greater proportion achieved goal titers of >100 IU/L compared with the low titer groups (pooled group 2 and 3; P < 0.05; Table 2 ).
The area under the receiver operating characteristic curve for the pretransplant anti-HBs level to predict the early attainment of anti-HBs levels >100 IU/L in the first 12 months after LT was 0.877 (95% confidence interval [CI], 0.779-0.974; P < 0.05). An anti- HBs cutoff level of 167 IU/L provided the maximum sum of sensitivity (83%) and specificity (93%) for the prediction. However, this value was affected by the maximum measurable anti-HBs level in our laboratory, which could only quantify up to 1600 IU/L, with titers above this range reported as >1600 IU/L in 16 patients. Hence, the cutoff for the pretransplant antiHBs level in the prediction of early achievement of posttransplant immunity was likely to be higher due to the above laboratory limitation.
INCIDENCE OF DNHB
DNHB occurred in 3 recipients in our cohort, all of whom were from group 3 while on lamivudine therapy with anti-HBs titers < 100 IU/L during follow-up. Of these patients, 2 were positive before transplant for antiHBc, and 2 did not receive posttransplant vaccinations (Table 3 ). All 3 recipients with DNHB were positive for serum HBV DNA without mutant strain. Liver function tests remained normal in all of them, so liver biopsy was not performed. One patient (LDLT 172) developed DNHB early (7 months after transplantation) before tapering of immunosuppressants. Another patient (LDLT 223) developed late DNHB after 51 months of lamivudine therapy, which prompted an attempt to stop lamivudine due to personal preference. Unfortunately, the patient became seropositive with HBsAg, prompting initiation of entecavir and successful suppression of the HBV DNA. No mutation of the tyrosine-methionineaspartate-aspartate locus of the HBV-RNA-dependent DNA polymerase (YMDD mutation) was detected in all 3 recipients who developed DNHB while on lamivudine. There were significant differences in the DNHBfree survival rates among the 3 groups (group 1, 2, and 3; log-rank, P 5 0.001; Fig. 2 ). On pairwise comparisons, groups 1 and 2 had significantly higher DNHBfree survival rates than group 3 (pairwise 1 versus 3, P 5 0.02; pairwise 2 versus 3, P 5 0.004). The 4-year *Only 15 patients in the high titer group had levels checked in the first year. † Two patients in the high titer group had no anti-HBs measured during follow-up. cumulative rate of DNHB was 27% in group 3, compared with 0% in groups 1 and 2. For comparison, during the study period, no DNHB incidence was found in the 82 recipients who received liver grafts from antiHBc-donors.
PREDICTIVE FACTORS FOR DNHB
Comparing the groups with (n 5 3) or without (n 5 68) DNHB, pretransplant recipient anti-HBs titer (98.9 versus 642.0 IU/L; P < 0.001), posttransplant peak anti-HBs titer (60.0 versus 735.0 IU/L; P < 0.001), and proportion of patients who achieved sustained posttransplant anti-HBs level of >100 IU/L (0% versus 78.8%; P 5 0.002) were significantly lower in the group with DNHB. Other studied variables (age, sex, severity of pretransplant liver disease, and rejection) were not statistically different between both groups.
Discussion
Our study shows that the use of HBV vaccination is an effective alternative for the prevention of DNHB if certain anti-HBs levels can be maintained with active immunization before and after LT. There was no incidence of DNHB in the patients who achieved posttransplant anti-HBs titers of >100 IU/L with active immunization during follow-up. In patients with low preoperative titers <1000 IU/L treated with lamivudine after transplant, the antiviral could be safely stopped after achieving sustained anti-HBs levels of >100 IU/L without any occurrence of DNHB. For patients with high pretransplant anti-HBs titers >1000 IU/L, the posttransplant follow-up involved only clinical surveillance without any prophylaxis. This approach is definitely more cost-effective and lowers the risk of emergence of antiviral-resistant strains. Although there are concerns over the development of vaccine escape mutants in recipients with high anti-HBs titers, (17, 18) so far most of the reported cases were from recipients who were given passive immunization (HBIG).
Currently, there is no consensus on the posttransplant target maintenance level of anti-HBs, which is considered protective against DNHB. Prior studies have found target ranges of >100 IU/L (pediatric) and >300 IU/L within the first year followed by >100 IU/L thereafter (adults) to be effective in preventing DNHB. (11, 15) Our study concurs with these findings with no incidence of DNHB documented in adult recipients with anti-HBs levels above 100 IU/L after transplantation.
Our study demonstrates that the most cost-effective way of attaining posttransplant immunity of anti-HBs levels >100 IU/L is by achieving high anti-HBs levels before transplantation. All patients with high pretransplant anti-HBs titers >1000 IU/L achieved posttransplant anti-HBs levels >100 IU/L within the first year and sustained this immunity at a steady level during follow-up. However, the optimal pretransplant antiHBs level for the prediction of posttransplant immunity could not be ascertained in this study due to the laboratory limitations discussed earlier. Previous studies in pediatric recipients (including from our center) have reported protective pretransplant anti-HBs levels of >200-1000 IU/L. (12) Because of the fact that the anti-HBs level will decline after transplantation as a result of immunosuppression, (19) we suggest aiming for higher pretransplant anti-HBs titers of >1000 IU/L in order to obtain sufficient posttransplant immunity.
Recipient age, cirrhosis, and immunosuppression can all diminish vaccine immunogenicity in the posttransplant period. (1, 20) An improved HBV vaccination response can be achieved with newer adjuvants and administering double doses of HBV recombinant vaccine. (21, 22) Our current study shows that the effectiveness of double doses of recombinant vaccine was fair, with response rates of 38% before transplant and up to 63% after transplant.
It is worth noting that 2 of 3 vaccine-nonresponsive DNHB patients were positive for both anti-HBc and anti-HBs. Some studies have suggested that antiHBc1/anti-HBs1 patients can safely receive antiHBc1 grafts without prophylaxis because the probability of DNHB infection is <2%. (8) Our data showed that posttransplant vaccination, if successful, could completely eliminate the risks of DNHB. Hence, posttransplant vaccination is still advised for antiHBc1/anti-HBs1 recipients. We do recognize certain limitations of our study. This approach is only suitable for patients with pretransplant stable conditions. In the posttransplant follow-up, it might be more logistically complicated than simple daily antiviral therapy, but we found it clinically effective and cost beneficial.
In conclusion, our study shows that active immunization is effective in preventing DNHB in adult LDLT. HBV vaccination should be administered in the pretransplant and posttransplant periods in all patients who receive liver grafts from anti-HBc1 donors. We propose the approach for the management of these patients (Fig. 1 ). For recipients with pretransplant anti-HBs titers of >1000 IU/L, no antiviral agent prophylaxis is required, but booster vaccinations are recommended after steroid withdrawal. Recipients with preoperative anti-HBs titers of <1000 IU/L require prophylaxis with lamivudine in addition to booster HBV vaccinations after steroid withdrawal regardless of preoperative anti-HBc serology. Lamivudine may be discontinued when the anti-HBs titers are >100 IU/L after posttransplant booster vaccination. Not only is this cost-effective, it is also safe and hence should be considered a viable alternative to the existing prophylactic regimens.
